2Seventy Bio

2Seventy Bio Net Change in Cash

Delisted

The Net Change in Cash of 2Seventy Bio (TSVT) as of Nov 16, 2026 is -3.82 M USD. In the previous year, Net Change in Cash was 4.39 M USD — a change of -186.91% (lower).

Net Change in Cash

-3.82 MUSD

YoY

-186.91%

Last updated:

Net Change in Cash of 2Seventy Bio is 2024 -3.82 M USD. Net Change in Cash of 2Seventy Bio was 2023 4.39 M USD. It decreases by -186.91% lower compared to the previous year.

The 2Seventy Bio Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
197.04 M USD
Jan 1, 2019
267.72 M USD
Jan 1, 2020
90.05 M USD
Jan 1, 2021
163.27 M USD
Jan 1, 2022
-59.21 M USD
Jan 1, 2023
4.39 M USD
Jan 1, 2024
-3.82 M USD
The 2Seventy Bio Net Change in Cash history
YEARNet Change in CashYoY
-3.82 MUSD-186.91%
4.39 MUSD-107.42%
-59.21 MUSD-136.26%
163.27 MUSD+81.30%
90.05 MUSD-66.36%
267.72 MUSD+35.87%
197.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2Seventy Bio Stock analysis

What does 2Seventy Bio do? 2seventy Bio, Inc. generates revenue through its cell and gene therapy programs, including SC-DARIC33 for pediatric relapsed and refractory acute myeloid leukemia and bbT369 for B-cell non-Hodgkin lymphoma. The company collaborates with Bristol Myers Squibb to deliver Abecma for multiple myeloma patients in the U.S., leveraging its T cell engineering and lentiviral vector technologies. Its clinical and preclinical programs, such as bbT4015 targeting MUC16, form the core of its product pipeline. The company focuses on developing targeted cellular therapies for cancer patients, with Bristol Myers Squibb as a key partner in commercializing Abecma. 2seventy Bio, Inc. operates in the biopharmaceutical sector, targeting patients with specific cancer types through its advanced therapies. Its products are developed using proprietary T cell engineering and lentiviral vector delivery systems. The company's revenue streams include clinical trial partnerships and potential future commercial sales of its therapies. Bristol Myers Squibb supports the U.S. distribution of Abecma, a key product in its portfolio. 2Seventy Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2Seventy Bio stock

Net Change in Cash of 2Seventy Bio is -3.82 M USD in 2024.

Net Change in Cash of 2Seventy Bio changed from 4.39 M USD to -3.82 M USD, representing a -186.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash 2Seventy Bio since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's 2Seventy Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — 2Seventy Bio

All Key Metrics — 2Seventy Bio